By Foo Yun Chee
作者：Foo Yun Chee
Brussels, June 26 (Reuters) - France-Based Cooper Consumer Health on Wednesday Secured EU Antitrust Approval to Buy U.S. Drugmaker Viatris' Vtrs.o European Over-the-Counter Drug Business After Agreeing to Sell Its Rights and Interests in an Infant Laxative Medicine and Earwax Removal Product.
法國 Cooper Consumer Health 本週三獲得歐盟反壟斷批准，收購美國藥品公司 viatris 的業務。在同意出售其嬰兒瀉藥和耳垢清洗產品的權利和利益後，法國 Cooper Consumer Health 完成了對歐洲非處方藥業務的收購。本次交易於去年10月宣佈，涉及36億美元。Viatris 出售了部分業務以專注於眼科醫療、胃腸病學和皮膚病學。
The Companies Announced the $3.6 Billion Deal Last October, With Viatris Selling Some of Its Businesses to Focus on Ophthalmology, Gastroenterology and Dermatology.
兩家公司在去年10月公佈了這筆價值36億美元的交易。交易Viatris 出售部分業務以專注於眼科醫療、胃腸病學和皮膚病學。
The European Commission, Which Acts as the EU Competition Enforcer, Said Cooper's Concessions Came After It Voiced Concerns About the High Combined Market Shares as a Result of the Deal and Also Insufficient Competitive Pressure From Rivals.
歐盟委員會作爲歐盟競爭事務執行機構表示，Cooper 在聲稱擔憂該交易所得到的高市場份額及來自競爭對手不足的競爭壓力後，提出了讓步。
Cooper Will Divest Its Rights, Title and Interests in Its Infant Laxative Medicine Bebegel and Its Rights, Title and Interests in Its Earwax Removal Product Otowaxol to Address the Commission's Competition Concerns, the EU Watchdog Said.
歐盟看門狗稱，Cooper 將放棄其嬰兒瀉藥 Bebegel 的權利、所有權和利益以及其耳垢清除產品 Otowaxol 的權利、所有權和利益，以解決委員會對於競爭的擔憂。
"the Remedies Offered by Viatris and Cooper Will Ensure That Competition on These Markets Remains Effective and That, Ultimately, Consumers in Portugal and Germany Do Not End up Paying Higher Prices for Certain Pharmaceutical Products," EU Antitrust Chief Margrethe Vestager Said.
歐盟反壟斷主管 Margrethe Vestager 表示：“vaitris 和 Cooper 提供的補救措施將確保這些市場上的競爭保持有效，並確保最終消費者在葡萄牙和德國不會爲某些藥品支付更高的價格。”
Viatris Was Formed Through the Merger of Mylan and Pfizer Inc's Pfe.n Upjohn Business and Deals With Generic and Key Branded Drugs in Its Portfolio, Including Arthritis Treatment Celebrex, Erectile Dysfunction Drug Viagra, Epilepsy Treatment Lyrica, and Antidepressant Zoloft.
Viatris 是由 Mylan 和 Pfizer 公司的 Upjohn 業務合併而成的，業務涉及仿製藥和主要品牌藥品，包括關節炎治療 Celebrex、勃起功能障礙藥品 Viagra、癲癇治療藥品 Lyrica 和抗抑鬱藥 Zoloft。Pfe.nUpjohn業務及其組合中所涉及的藥品，包括治療關節炎的Celebrex，治療勃起功能障礙的Viagra，抗癲癇的Lyrica，以及抗抑鬱的Zoloft。
(Reporting by Foo Yun Chee)
（報道作者:付雲翀）
((Foo.yunchee@Thomsonreuters.com; +32 2 585 2866; Reuters Messaging: Foo.yunchee.thomsonreuters.com@Reuters.net))
((Foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters通訊:foo.yunchee.thomsonreuters.com@reuters.net))